Debra Mccarty

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

C. Farthing, D. Shortino, B. Grinsztejn, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study

A. Lazzarin, J. Currier, N. Clumeck, 2008, Antiviral Therapy.

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136) *

A. Lazzarin, A. Lamarca, K. Adkison, 2009, HIV medicine.